Figure 1.

Patient disposition in the teduglutide (TED) pediatric core and extension clinical trials. TED was provided as a once‐daily subcutaneous injection. Dotted arrows represent a gap between the 12‐week core study and the subsequent extension study. SOC, standard of care.